Imricor Medical Systems (ASX:IMR) submitted its Vision-MR diagnostic catheter for approval under the US Food and Drug Administration's (FDA) 510(k) premarket notification pathway, according to a Monday Australian bourse filing.
The diagnostic catheter is designed to be used under real-time magnetic resonance imaging (MRI) guidance and is a key component of Imricor's full platform of MRI-compatible electrophysiology devices, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.